Could a dye reveal hidden scarring in Crohn's patients?

NCT ID NCT07152431

Recruiting now Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new imaging method using a special dye (FAPI) to detect bowel scarring in people with Crohn's disease. Scarring affects up to half of patients and often leads to surgery, but current tests can't spot it early. The study will involve 30 adults starting biologic treatment, who will receive PET/CT scans to see if the dye can track scarring activity. If it works, this could pave the way for new drugs that prevent permanent bowel damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAPI (fibrosis associated protein inhibitor) dye used with PET/CT imaging
What this could lead to: If successful, this could be the first non-invasive way to detect and track bowel scarring in Crohn's disease, helping develop new anti-fibrotic treatments.
What could go wrong: This is a small, early observational study with only 30 participants. It tests a detection method, not a treatment, so it may not directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Locations

NHS Lothian
RECRUITING

Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.